Mesoporous silica compositions for modulating immune responses
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/00
A61K-009/16
A61K-038/18
A61K-038/19
A61K-039/39
A61K-009/00
출원번호
US-0394552
(2013-04-16)
등록번호
US-9937249
(2018-04-10)
국제출원번호
PCT/US2013/036827
(2013-04-16)
국제공개번호
WO2013/158673
(2013-10-24)
발명자
/ 주소
Kim, Jaeyun
Li, Weiwei Aileen
Mooney, David J.
출원인 / 주소
President and Fellows of Harvard College
대리인 / 주소
Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
인용정보
피인용 횟수 :
0인용 특허 :
44
초록
A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen.
대표청구항▼
1. A composition comprising mesoporous silica rods comprising an immune cell recruitment compound comprising granulocyte macrophage-colony stimulating factor (GM-CSF), chemokine (C-C motif) ligand 21 (CCL-21), chemokine (C-C motif) ligand 19 (CCl-19), or a FMS-like tyrosine kinase 3 (Flt-3) ligand;
1. A composition comprising mesoporous silica rods comprising an immune cell recruitment compound comprising granulocyte macrophage-colony stimulating factor (GM-CSF), chemokine (C-C motif) ligand 21 (CCL-21), chemokine (C-C motif) ligand 19 (CCl-19), or a FMS-like tyrosine kinase 3 (Flt-3) ligand; andan immune cell activation compound comprising a TLR agonist,wherein said rods comprise a length of 25 μm to 500 μm and pores of between 2 nm to 50 nm in diameter, andwherein said rods are stacked into a 3D structure, wherein said structure comprises micro spaces that allow for immune cell infiltration or trafficking. 2. An injectable composition comprising mesoporous silica rods comprising an immune cell recruitment compound comprising granulocyte macrophage-colony stimulating factor (GM-CSF), chemokine (C-C motif) ligand 21 (CCL-21), chemokine (C-C motif) ligand 19 (CCl-19), or a FMS-like tyrosine kinase 3 (Flt-3) ligand; andan immune cell activation compound comprising a TLR agonist,wherein said rods comprise a length of 25 μm to 500 μm and pores of between 2 nm to 50 nm in diameter, andwherein said rods self-assemble into a 3D structure in vivo, and wherein said structure comprises micro spaces that allow for immune cell infiltration or trafficking. 3. The composition of claim 1, wherein said TLR agonist comprises a pathogen associated molecular pattern (PAMP). 4. The composition of claim 3, wherein said PAMP comprises a bacterially-derived immunomodulator. 5. The composition of claim 1, wherein said TLR agonist comprises a nucleic acid, a lipid, double stranded deoxyribonucleic acid (DNA), double stranded ribonucleic acid (RNA), or a lipopolysaccharide. 6. The composition of claim 1, wherein said TLR agonist comprises a TLR3 agonist or a TLR9 agonist. 7. The composition of claim 1, wherein said rods comprise pores of between 2-50 nm in diameter. 8. The composition of claim 1, wherein said rods comprise pores of between 5-25 nm in diameter. 9. The composition of claim 1, wherein said rods comprise pores of between 5-10 nm in diameter. 10. The composition of claim 1, wherein said rods comprise pores of approximately 8 nm in diameter. 11. The composition of claim 1, wherein said rods comprise a length of 25 μm to 250 μm. 12. The composition of claim 1, wherein said rods comprise a length of 80 μm to 120 μm. 13. The composition of claim 1, wherein said recruitment compound comprises GM-CSF. 14. The composition of claim 1, wherein said composition further comprises an antigen. 15. The composition of claim 14, wherein said antigen comprises a tumor antigen. 16. The composition of claim 15, wherein said tumor antigen is present in a tumor cell lysate. 17. The composition of claim 14, wherein said antigen comprises MAGE-1, MART-1/melana, tyrosinase, ganglioside, gp100, GD-2, O-acetylated GD-3, GM-2, Mucin 1, Sos1, protein kinase C-binding protein, reverse transcriptase protein, AKAP protein, VRK1, KIAA1735, T7-1, T11-3, T11-9, Homo sapiens telomerase ferment (hTRT), Cytokeratin-19 (CYFRA21-1), squamous cell carcinoma antigen 1 (SCCA-1), Protein T4-A, squamous cell carcinoma antigen 2 (SCCA-2), ovarian carcinoma antigen CA125 (1A1-3B) (KIAA0049), CTCL tumor antigen se1-1, CTCL tumor antigen se14-3, CTCL tumor antigen se20-4, CTCL tumor antigen se20-9, CTCL tumor antigen se33-1, CTCL tumor antigen se37-2, CTCL tumor antigen se57-1, CTCL tumor antigen se89-1, prostate specific membrane antigen, 5T4 oncofetal trophoblast glycoprotein, Orf73 Kaposi's sarcoma-associated herpesvirus, MAGE-C1 (cancer/testis antigen CT7), MAGE-B1 Antigen (MAGE-XP Antigen), DAM10, MAGE-B2 Antigen (DAM6), MAGE-2 Antigen, MAGE-4a antigen, MAGE-4b antigen, colon cancer antigen NY-CO-45, lung cancer antigen NY-LU-12 variant A, cancer associated surface antigen, adenocarcinoma antigen ART1, paraneoplastic associated brain-testis-cancer antigen, onconeuronal antigen MA2, paraneoplastic neuronal antigen, neuro oncological ventral antigen 2 (NOVA2), hepatocellular carcinoma antigen gene 520, tumor-associated antigen CO-029, tumor-associated antigen MAGE-X2, synovial sarcoma, X breakpoint 2, squamous cell carcinoma antigen recognized by T cell, seriologically defined colon cancer antigen 1, seriologically defined breast cancer antigen NY-BR-15, seriologically defined breast cancer antigen NY-BR-16, Chromogranin A; parathyroid secretory protein 1, DUPAN-2, CA 19-9, CA 72-4, CA 195, or carcinoembryonic antigen (CEA). 18. The composition of claim 1, wherein said rods comprise a length of 30 μm to 100 μm. 19. The composition of claim 1, wherein said rods comprise a length of 50 μm to 250 μm. 20. The composition of claim 2, wherein said TLR agonist comprises a pathogen associated molecular pattern (PAMP). 21. The composition of claim 20, wherein said PAMP comprises a bacterially-derived immunomodulator. 22. The composition of claim 2, wherein said TLR agonist comprises a nucleic acid, a lipid, double stranded deoxyribonucleic acid (DNA), double stranded ribonucleic acid (RNA), or a lipopolysaccharide. 23. The composition of claim 2, wherein said TLR agonist comprises a TLR3 agonist or a TLR9 agonist. 24. The composition of claim 2, wherein said rods comprise pores of between 2-50 nm in diameter. 25. The composition of claim 2, wherein said rods comprise pores of between 5-25 nm in diameter. 26. The composition of claim 2, wherein said rods comprise pores of between 5-10 nm in diameter. 27. The composition of claim 2, wherein said rods comprise pores of approximately 8 nm in diameter. 28. The composition of claim 2, wherein said rods comprise a length of 25 μm to 250 μm. 29. The composition of claim 2, wherein said rods comprise a length of 80 μm to 120 μm. 30. The composition of claim 2, wherein said recruitment compound comprises GM-CSF. 31. The composition of claim 2, wherein said composition further comprises an antigen. 32. The composition of claim 31, wherein said antigen comprises a tumor antigen. 33. The composition of claim 32, wherein said tumor antigen is present in a tumor cell lysate. 34. The composition of claim 31, wherein said antigen comprises MAGE-1, MART-1/melana, tyrosinase, ganglioside, gp100, GD-2, O-acetylated GD-3, GM-2, Mucin 1, Sos1, protein kinase C-binding protein, reverse transcriptase protein, AKAP protein, VRK1, KIAA1735, T7-1, T11-3, T11-9, Homo sapiens telomerase ferment (hTRT), Cytokeratin-19 (CYFRA21-1), squamous cell carcinoma antigen 1 (SCCA-1), Protein T4-A, squamous cell carcinoma antigen 2 (SCCA-2), ovarian carcinoma antigen CA125 (1A1-3B) (KIAA0049), CTCL tumor antigen se1-1, CTCL tumor antigen se14-3, CTCL tumor antigen se20-4, CTCL tumor antigen se20-9, CTCL tumor antigen se33-1, CTCL tumor antigen se37-2, CTCL tumor antigen se57-1, CTCL tumor antigen se89-1, prostate specific membrane antigen, 5T4 oncofetal trophoblast glycoprotein, Orf73 Kaposi's sarcoma-associated herpesvirus, MAGE-C1 (cancer/testis antigen CT7), MAGE-B1 Antigen (MAGE-XP Antigen), DAM10, MAGE-B2 Antigen (DAM6), MAGE-2 Antigen, MAGE-4a antigen, MAGE-4b antigen, colon cancer antigen NY-CO-45, lung cancer antigen NY-LU-12 variant A, cancer associated surface antigen, adenocarcinoma antigen ART1, paraneoplastic associated brain-testis-cancer antigen, onconeuronal antigen MA2, paraneoplastic neuronal antigen, neuro oncological ventral antigen 2 (NOVA2), hepatocellular carcinoma antigen gene 520, tumor-associated antigen CO-029, tumor-associated antigen MAGE-X2, synovial sarcoma, X breakpoint 2, squamous cell carcinoma antigen recognized by T cell, seriologically defined colon cancer antigen 1, seriologically defined breast cancer antigen NY-BR-15, seriologically defined breast cancer antigen NY-BR-16, Chromogranin A; parathyroid secretory protein 1, DUPAN-2, CA 19-9, CA 72-4, CA 195, or carcinoembryonic antigen (CEA). 35. The composition of claim 2, wherein said rods comprise a length of 30 μm to 100 μm. 36. The composition of claim 2, wherein said rods comprise a length of 50 μm to 250 μm. 37. The composition of claim 1, wherein said rods comprise a diameter from 1.5 μm to 10 μm. 38. The composition of claim 2, wherein said rods comprise a diameter from 1.5 μm to 10 μm.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (44)
Porcelli, Steven A.; Venkataswamy, Manjunatha M., Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof.
Pardoll Drew ; Azhari Rosa,ILX ; Leong Kam W. ; Golumbe Paul K ; Jaffee Elizabeth ; Levitsky Hyam ; Lazenby Audrey, Controlled release of pharmaceutically active substances for immunotherapy.
Gaur Amitabh ; Conlon Paul ; Ling Nicholas C. ; Staehelin Theophil,CHX ; Crowe Paul D., Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein.
Murphy, William L.; Mooney, David J.; Kohn, David H.; Spalding, Gabriel C.; Dearing, Matthew T., Mineral and cellular patterning on biomaterial surfaces.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
Hackam, David J.; Gribar, Steven C., Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.